Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling

Chemotherapy-Induced Ca 2+ Release Stimulates Breast Cancer Stem Cell Enrichment

(2017) Haiquan Lu et al.   Cell Reports

The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells

(2016) Hongyao Zhang et al.   CANCER BIOLOGY & THERAPY

Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?

(2016) Paola Bertocchi et al.   JOURNAL OF CHEMOTHERAPY

Influence of microRNA-34a on proliferation, invasion and metastasis of HCT116 cells

(2016) Chunyan Li et al.   Molecular Medicine Reports

ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells

(2016) Lijun Ma et al.   TUMOR BIOLOGY

In Situ Characterization of Bak Clusters Responsible for Cell Death Using Single Molecule Localization Microscopy

(2016) Yusuke Nasu et al.   Scientific Reports

Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

(2015) Tadeu Ferreira Paiva et al.   BMC CANCER

Therapeutic strategies targeting cancer stem cells

(2015) Go J. Yoshida et al.   CANCER SCIENCE

Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours

(2015) Matt Shirley et al.   DRUGS

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET

(2015) BIN WEI et al.   Molecular Medicine Reports

Bax protein may influence the invasion of colorectal cancer

(2014) Anna Pryczynicz   WORLD JOURNAL OF GASTROENTEROLOGY

Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation

(2013) Go J. Yoshida et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Colorectal cancer

(2013) Hermann Brenner et al.   LANCET

Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy

(2012) Go J Yoshida et al.   BMC CANCER

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

(2011) Can Liu et al.   NATURE MEDICINE

Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells

(2011) Dara Nalls et al.   PLoS One

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER